Today's Stocks Driving Success For The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 0 points (0.0%) at 18,120 as of Tuesday, June 23, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,606 issues advancing vs. 1,375 declining with 175 unchanged.

The Drugs industry currently sits down 0.6% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Novavax ( NVAX), up 7.9%, Vertex Pharmaceuticals ( VRTX), up 1.6%, Perrigo ( PRGO), up 1.5%, Shire ( SHPG), up 0.8% and Sanofi ( SNY), up 0.8%. On the negative front, top decliners within the industry include Biomarin Pharmaceutical ( BMRN), down 1.9%, Alnylam Pharmaceuticals ( ALNY), down 1.9%, Incyte ( INCY), down 1.3% and Novo Nordisk A/S ( NVO), down 1.1%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Allergan ( AGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Allergan is up $3.81 (1.2%) to $311.06 on average volume. Thus far, 1.1 million shares of Allergan exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $308.07-$312.37 after having opened the day at $308.20 as compared to the previous trading day's close of $307.25.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. Allergan has a market cap of $118.7 billion and is part of the health care sector. Shares are up 19.4% year-to-date as of the close of trading on Monday. Currently there are 15 analysts who rate Allergan a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Allergan as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Get the full Allergan Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Allergan ( ACT) is up $3.81 (1.2%) to $311.06 on average volume. Thus far, 1.1 million shares of Allergan exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $308.07-$312.37 after having opened the day at $308.20 as compared to the previous trading day's close of $307.25.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Actavis plc develops, manufactures, and sells generic, brand, and biosimilar pharmaceuticals. It offers over-the-counter products. The company also provides biosimilar products in women's health, oncology, and other therapeutic categories. Allergan has a market cap of $117.3 billion and is part of the health care sector. Shares are up 16.1% year-to-date as of the close of trading on Monday. Currently there are 15 analysts who rate Allergan a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Allergan Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Pfizer ( PFE) is up $0.20 (0.6%) to $34.50 on light volume. Thus far, 9.0 million shares of Pfizer exchanged hands as compared to its average daily volume of 24.4 million shares. The stock has ranged in price between $34.34-$34.59 after having opened the day at $34.41 as compared to the previous trading day's close of $34.31.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Pfizer has a market cap of $210.5 billion and is part of the health care sector. Shares are up 10.1% year-to-date as of the close of trading on Monday. Currently there are 8 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Pfizer Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

More from Markets

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Video: Stop Using Student Loan Money to Buy Bitcoin

Video: Stop Using Student Loan Money to Buy Bitcoin

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio